Frontlight ResearchEarly access
Taking people in United StatesPhase 1
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
Key facts
- Who runs it
- Immusoft of CA, Inc.
- Where
- Minneapolis and Oakland, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 11 people, planned
- Started
- 12 Apr 2023
- Expected to end
- 1 Jun 2044
- Type of study
- Interventional, 2 groups
- Treatments tested
- Autologous Plasmablasts (B cells)
- Record updated
- 17 July 2026
Who can take part
- Age
- 10 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Diagnosis of Mucopolysaccharidosis type I Hurler-Scheie or Scheie syndrome
- Age ≥ 10 years at time of study registration
- Creatinine clearance, calculated or measured directly, that is >60ml/min/1.73m2
- Ejection fraction ≥ 40% by echocardiogram
- Must commit to traveling to the study site for the necessary follow-up evaluations
- Must agree to stay <45-minute drive from the study site for a minimum of 5 days after cell infusion
Who cannot take part
- Underwent a previous hematopoietic stem cell transplant (HSCT)
- Known familial inherited cancer syndrome. Suspected cases will be investigated, per the physicians discretion, using relevant genetic tests to determine presence of germline mutations
- History of B cell related cancer, EBV lymphoproliferative disease or autoimmune disorders
- Evidence of active graft-vs-host disease
- Any medical condition likely to interfere with assessment of safety or efficacy of the study treatment
- Requirement for systemic immune suppression
- Requirement for continuous supplemental oxygen
- In the investigator's judgement, the subject is unlikely to complete all protocol-required study visits or procedures, including follow up visits, or comply with the study requirements for participation; Other protocol defined inclusion/exclusion criteria may apply
This trial is currently available in United States.
- University of MinnesotaMinneapolis, United StatesContact: Paul Orchard, MD (principal investigator)Taking people
- UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Daniel SchraderTaking people
About the trial
What the trial wants to find out
A first-in-human study using ISP-001 in patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
The 2 groups in the trial
- Autologous Plasmablasts (B cells) - Cohort - Target Dose ATreatment being tested
Dose Level: 5 x 10e7 cells/kg on Day 0
Treatment: Autologous Plasmablasts (B cells)
- Autologous Plasmablasts (B cells) - Cohort - Target Dose BTreatment being tested
Dose Level: Between 1 x 10e8 or to 2 x 10e8 cells/kg on Day 0
Treatment: Autologous Plasmablasts (B cells)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients With Mucopolysaccharidosis Type I Hurler-Scheie and Scheie
- Record updated
- 17 July 2026